

**IN THE CLAIMS:**

Claims 5 and 8-11 have been amended herein. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

1. (Previously presented) The peptide of claim 8, the peptide comprising SEQ ID NO:1, or its acetate salt.

2. (Previously presented) The peptide of claim 8, the peptide comprising SEQ ID NO:2, or its acetate salt.

3. (Previously presented) The peptide of claim 8, the peptide comprising SEQ ID NO:3, or an acetate salt thereof.

4. (Previously presented) The peptide of claim 8, the peptide comprising SEQ ID NO:4, or its acetate salt.

5. (Currently amended) A peptide or its acetate salt, the sequence of the peptide ~~comprises~~ comprising SEQ ID NO:5, and the sequence of the peptide is at least 30% conserved with the peptide of claim 1.

6. (Previously presented) A method comprising applying a pharmaceutical composition, wherein the pharmaceutical composition comprises the peptide of claim 1, and wherein the pharmaceutical composition is used as an anti-inflammatory drug or immunological inhibitor.

7. (Previously presented) A method of preparing the peptide of claim 1, the method comprising: obtaining active peptides or proteins of pharmaceutical value by separating and purifying proteins or polypeptides from musk; determining their pharmaceutical effects by means of pharmacodynamical analysis; identifying the amino acid sequences; then, constructing a cDNA library using active components or tissues from animals or plants to obtain target genes encoding the peptides; obtaining the amino acid sequences of the peptides.

8. (Currently amended) A peptide isolated from the active principles of natural musk, or salts thereof, the sequence of the peptide ~~comprises~~comprising SEQ ID NO:5.

9. (Currently amended) A peptide or its acetate salt, the sequence of the peptide ~~comprises~~comprising SEQ ID NO:5, and the sequence of the peptide is at least 30% conserved with the peptide of claim 2.

10. (Currently amended) A peptide or its acetate salt, the sequence of the peptide ~~comprises~~comprising SEQ ID NO:5, and the sequence of the peptide is at least 30% conserved with the peptide of claim 3.

11. (Currently amended) A peptide or its acetate salt, the sequence of the peptide ~~comprises~~comprising SEQ ID NO:5, and the sequence of the peptide is at least 30% conserved with the peptide of claim 4.

12. (Previously presented) A method comprising applying a pharmaceutical composition, wherein the pharmaceutical composition comprises the peptide of claim 2, and wherein the pharmaceutical composition is used as an anti-inflammatory drug or immunological inhibitor.

13. (Previously presented) A method comprising applying a pharmaceutical composition, wherein the pharmaceutical composition comprises the peptide of claim 3, and wherein the pharmaceutical composition is used as an anti-inflammatory drug or immunological inhibitor.

14. (Previously presented) A method comprising applying a pharmaceutical composition, wherein the pharmaceutical composition comprises the peptide of claim 4, and wherein the pharmaceutical composition is used as an anti-inflammatory drug or immunological inhibitor.

15. (Previously presented) A method of preparing the peptide of claim 2, the method comprising: obtaining active peptides or proteins of pharmaceutical value by separating and purifying proteins or polypeptides from musk; determining their pharmaceutical effects by means of pharmacodynamical analysis; identifying the amino acid sequences; then, constructing a cDNA library using active components or tissues from animals or plants to obtain target genes encoding the peptides; obtaining the amino acid sequences of the peptides.

16. (Previously presented) A method of preparing the peptide of claim 3, the method comprising: obtaining active peptides or proteins of pharmaceutical value by separating and purifying proteins or polypeptides from musk; determining their pharmaceutical effects by means of pharmacodynamical analysis; identifying the amino acid sequences; then, constructing a cDNA library using active components or tissues from animals or plants to obtain target genes encoding the peptides; obtaining the amino acid sequences of the peptides.

17. (Previously presented) A method of preparing the peptide of claim 4, the method comprising: obtaining active peptides or proteins of pharmaceutical value by separating and purifying proteins or polypeptides from musk; determining their pharmaceutical effects by means of pharmacodynamical analysis; identifying the amino acid sequences; then, constructing a cDNA library using active components or tissues from animals or plants to obtain target genes encoding the peptides; obtaining the amino acid sequences of the peptides.